^Kane JM, Smith JM (April 1982). “Tardive dyskinesia: prevalence and risk factors, 1959 to 1979”. Archives of General Psychiatry39 (4): 473–81. PMID 6121548.
^Wszola BA, Newell KM, Sprague RL (August 2001). “Risk factors for tardive dyskinesia in a large population of youths and adults”. Experimental and Clinical Psychopharmacology9 (3): 285–96. doi:10.1037/1064-1297.9.3.285. PMID 11534539.
^Yassa R (September 1988). “Tardive dyskinesia and anticholinergic drugs. A critical review of the literature”. L'Encéphale14 Spec No: 233–9. PMID 3063514.
… The data regarding other nonsteroidal anti-inflammatory drugs (NSAIDs) are conflicting,… Parkinson disease (PD) is the most common cause of parkinsonism, a syndrome manifested by rest tremor, rigidity, bradykinesia, and postural instability. The disorder was first described by James Parkinson …
… be useful as a prophylactic treatment for migraine visual aura without headache. In case reports, agents with efficacy for persistent visual aura include acetazolamide, nimodipine, isoproterenol, lamotrigine … dementia with Lewy bodies (DLB) and are also common in Parkinson disease (PD) .…
… and how oncologic drugs are developed. Studies are now investigating whether drugs affect the stem-like cells and not just tumor bulk, and whether agents can target distinctive… ES cell-derived somatic cells has been demonstrated in animal models of retinal blindness, Parkinson disease, Huntington disease, spinal cord injury, myocardial infarction, and type I diabetes mellitus …
… A variety of antiparkinson drugs, most notably anticholinergic agents, dopaminergic agents,… dysfunction is common in Parkinson disease (PD) and exists on a continuum of severity; prevalence increases with the duration of the movement disorder.…
… The major drugs available for the treatment of PD motor symptoms include: Levodopa; Dopamine agonists; Monoamine oxidase (MAO) B inhibitors; Anticholinergic agents; Amantadine; Catechol-O-methyl… Parkinson disease (PD) and the parkinsonian neurodegenerative disorders typically develop relatively slowly over several years.…
<p>【はじめに・目的】</p><p>近年,パーキンソン病(PD)の運動症状に対し非侵襲的治療として反復経頭蓋磁気刺激(repetitive transcranial magnetic stimulation:rTMS)治療の効果が報告されており、関心が高まっている.また,非薬物療法としてリハビリテーション(リハ)は治療の一つとして確立されつつあるが,それらを併 …